

Norio Komatsu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8081710/publications.pdf>

Version: 2024-02-01

119
papers

2,144
citations

304602

22
h-index

265120

42
g-index

124
all docs

124
docs citations

124
times ranked

3074
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. <i>Blood</i> , 2016, 127, 1307-1316.	0.6	224
2	Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. <i>FEBS Journal</i> , 1999, 264, 397-406.	0.2	198
3	Leukocyte concentration and composition in platelet-rich plasma (PRP) influences the growth factor and protease concentrations. <i>Journal of Orthopaedic Science</i> , 2016, 21, 683-689.	0.5	108
4	A Member of Forkhead Transcription Factor FKHL1 Is a Downstream Effector of STI571-induced Cell Cycle Arrest in BCR-ABL-expressing Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 6411-6419.	1.6	97
5	The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. <i>Annals of Hematology</i> , 2017, 96, 1653-1665.	0.8	92
6	Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. <i>Oncogene</i> , 2001, 20, 8249-8257.	2.6	74
7	Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 774-776.	0.2	69
8	FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia. <i>Blood</i> , 2010, 115, 3787-3795.	0.6	67
9	Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. <i>Blood Advances</i> , 2022, 6, 238-247.	2.5	61
10	Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation. <i>Leukemia</i> , 2019, 33, 122-131.	3.3	54
11	MIP-1 β /CCL3-mediated maintenance of leukemia-initiating cells in the initiation process of chronic myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2013, 210, 2661-2673.	4.2	52
12	JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. <i>Haematologica</i> , 2015, 100, e46-e48.	1.7	50
13	Megakaryocytopoiesis in vitro of patients with essential thrombocythaemia: effect of plasma and serum on megakaryocyte colony formation. <i>British Journal of Haematology</i> , 1986, 64, 241-252.	1.2	44
14	Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface. <i>Leukemia</i> , 2020, 34, 499-509.	3.3	39
15	Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. <i>International Journal of Hematology</i> , 2018, 107, 673-680.	0.7	33
16	MIP-1 β /CCL3-expressing basophil-lineage cells drive the leukemic hematopoiesis of chronic myeloid leukemia in mice. <i>Blood</i> , 2016, 127, 2607-2617.	0.6	32
17	Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy. <i>Blood</i> , 2018, 132, 4-4.	0.6	32
18	Inhibition of the NAD-Dependent Protein Deacetylase SIRT2 Induces Granulocytic Differentiation in Human Leukemia Cells. <i>PLoS ONE</i> , 2013, 8, e57633.	1.1	31

#	ARTICLE	IF	CITATIONS
19	JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. <i>International Journal of Hematology</i> , 2014, 99, 625-634.	0.7	29
20	Somatic mutations of calreticulin in myeloproliferative neoplasms. <i>International Journal of Hematology</i> , 2017, 105, 743-747.	0.7	29
21	Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. <i>Leukemia Research</i> , 2019, 79, 38-44.	0.4	25
22	Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	24
23	Increased SLAMF7 ^{high} monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab. <i>Blood</i> , 2019, 134, 814-825.	0.6	24
24	Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e810-e816.	0.2	23
25	A functional role of mitogen-activated protein kinases, Erk1 and Erk2, in the differentiation of a human leukemia cell line, UT-7/GM: A possible key factor for cell fate determination toward erythroid and megakaryocytic lineages. <i>International Journal of Hematology</i> , 2001, 73, 78-83.	0.7	22
26	Dysregulation of the <i>MIRLET7</i> / <i>HMGA2</i> axis with methylation of the <i>CDKN2A</i> promoter in myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2015, 168, 338-349.	1.2	22
27	Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-trans-retinoic Acid-induced Granulocytic Differentiation in Leukemia Cells. <i>Journal of Biological Chemistry</i> , 2017, 292, 2815-2829.	1.6	21
28	Rapid and easy detection of low-level resistance to vancomycin in methicillin-resistant <i>Staphylococcus aureus</i> by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. <i>PLoS ONE</i> , 2018, 13, e0194212.	1.1	20
29	Identification of AIM2 as a downstream target of JAK2V617F. <i>Experimental Hematology and Oncology</i> , 2015, 5, 2.	2.0	19
30	Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. <i>International Journal of Hematology</i> , 2015, 101, 148-153.	0.7	19
31	Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations. <i>British Journal of Haematology</i> , 2018, 181, 791-802.	1.2	19
32	Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms. <i>Cancer Science</i> , 2017, 108, 1907-1912.	1.7	18
33	Alternately binding probe competitive PCR as a simple, cost-effective, and accurate quantification method for JAK2V617F allele burden in myeloproliferative neoplasms. <i>Leukemia Research</i> , 2011, 35, 1632-1636.	0.4	17
34	Anemia attributed to vitamin B6 deficiency in post-pancreaticoduodenectomy patients. <i>Pancreatology</i> , 2015, 15, 81-83.	0.5	17
35	Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. <i>Blood Advances</i> , 2017, 1, 1001-1015.	2.5	16
36	Acquired Factor V Inhibitor Developing after Treatment with Dabigatran Etxilate Methanesulfonate: A Case Report and Review of the Literature. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2014, 30, 275-279.	0.3	15

#	ARTICLE	IF	CITATIONS
37	Detection of MPLW515L/K Mutations and Determination of Allele Frequencies with a Single-Tube PCR Assay. <i>PLoS ONE</i> , 2014, 9, e104958.	1.1	14
38	The role of calreticulin mutations in myeloproliferative neoplasms. <i>International Journal of Hematology</i> , 2020, 111, 200-205.	0.7	14
39	The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. <i>Cancer Medicine</i> , 2020, 9, 8931-8939.	1.3	14
40	A case of recurrent autoimmune hemolytic anemia during remission associated with acute pure red cell aplasia and hemophagocytic syndrome due to human parvovirus B19 infection successfully treated by steroid pulse therapy with a review of the literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 2624-35.	0.5	14
41	Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis. <i>International Journal of Hematology</i> , 2017, 105, 309-317.	0.7	13
42	Specific mechanisms of subarachnoid hemorrhage accompanied by ischemic stroke in essential thrombocythemia: two case reports and a literature review. <i>Journal of Neurology</i> , 2019, 266, 1869-1878.	1.8	13
43	Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin. <i>Cancer Science</i> , 2020, 111, 2682-2688.	1.7	13
44	The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: Comparison with the 2008 WHO diagnostic criteria. <i>American Journal of Hematology</i> , 2017, 92, E128-E130.	2.0	12
45	Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy. <i>Haematologica</i> , 2019, 104, e506-e509.	1.7	12
46	Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review. <i>Cancer Science</i> , 2021, 112, 2607-2624.	1.7	12
47	Patient with Refractory Multiple Myeloma Developing Eosinophilia after Lenalidomide Treatment and Lung Cancer 9Months Later: Case Report and Review of the Literature. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2014, 30, 264-270.	0.3	11
48	Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan. <i>European Journal of Haematology</i> , 2019, 102, 516-520.	1.1	11
49	Effects of their <i>in vivo</i> Administration of Recombinant Human Granulocyte Colony-stimulating Factor Following Cytotoxic Chemotherapy on Granulocytic Precursors in Patients with Malignant Lymphoma I. <i>Japanese Journal of Cancer Research</i> , 1989, 80, 577-582.	1.7	10
50	<i>CREB3L1</i> overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Cancer Science</i> , 2021, 112, 884-892.	1.7	10
51	<i>JAK2</i> exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera. <i>British Journal of Haematology</i> , 2019, 187, e27-e31.	1.2	9
52	Efficacy and safety of ferric citrate hydrate compared with sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3 non-inferiority study. <i>International Journal of Hematology</i> , 2021, 114, 8-17.	0.7	9
53	Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-CHOP therapy and intrathecal administration: a case report and review of literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 3363-9.	0.5	9
54	Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score. <i>Leukemia and Lymphoma</i> , 2018, 59, 1105-1112.	0.6	8

#	ARTICLE	IF	CITATIONS
55	Vitamin B6 deficiency is prevalent in primary and secondary myelofibrosis patients. International Journal of Hematology, 2019, 110, 543-549.	0.7	8
56	Interferon therapy for pregnant patients with essential thrombocythemia in Japan. International Journal of Hematology, 2021, 113, 106-111.	0.7	8
57	Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. International Journal of Hematology, 2022, 116, 215-227.	0.7	8
58	Confirmation of bone marrow engraftment by detection of M/N blood group antigens on erythroblasts in erythroid bursts. British Journal of Haematology, 1988, 69, 329-333.	1.2	7
59	The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort. European Journal of Haematology, 2018, 100, 544-549.	1.1	7
60	Inhibitory Effect of BQ-123 on Endothelin-1-Stimulated Mitogen-Activated Protein Kinase and Cell Growth of Rat Vascular Smooth Muscle Cells.. Hypertension Research, 1996, 19, 23-30.	1.5	7
61	Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study. International Journal of Hematology, 2022, 115, 208-221.	0.7	7
62	Autologous Peripheral Blood Stem Cell Transplantation for Adults with B-Lineage Acute Lymphoblastic Leukemia: A Pilot Study. Leukemia and Lymphoma, 2000, 38, 103-111.	0.6	6
63	Culture of Megakaryocytic Cell Lines: Uses and Limitations. , 2004, 272, 361-374.		6
64	Successful Long-Term Ibrutinib Treatment in a Hemodialysis Patient With Leukemic Nonnodal Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e176-e178.	0.2	6
65	Cell-autonomous megakaryopoiesis associated with polyclonal hematopoiesis in triple-negative essential thrombocythemia. Scientific Reports, 2021, 11, 17702.	1.6	6
66	Thrombopoietin Initiates Demethylation-Based Transcription of GP6 during Megakaryocyte Differentiation.. Blood, 2004, 104, 3520-3520.	0.6	6
67	Diffuse large B-cell lymphoma solely involving bilateral adrenal glands and stomach: report of an extremely rare case with review of the literature. International Journal of Clinical and Experimental Pathology, 2014, 7, 8190-7.	0.5	6
68	APOA-1 is a Novel Marker of Erythroid Cell Maturation from Hematopoietic Stem Cells in Mice and Humans. Stem Cell Reviews and Reports, 2011, 7, 43-52.	5.6	5
69	Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis. International Journal of Hematology, 2018, 107, 92-97.	0.7	5
70	Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia. Expert Review of Hematology, 2019, 12, 285-293.	1.0	5
71	Phase II study of FLAGM (fludarabine+high-dose cytarabine+granulocyte colony-stimulating) Tj ETQq1 1 0.784314 Hematology, 2019, 109, 418-425.	0.7	5
72	Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis. International Journal of Hematology, 2021, 113, 500-507.	0.7	5

#	ARTICLE	IF	CITATIONS
73	Expansion of senescent megakaryocyte-lineage cells maintains CML cell leukemogenesis. <i>Blood Advances</i> , 2020, 4, 6175-6188.	2.5	5
74	Melting Curve Analysis after T Allele Enrichment (MelcaTle) as a Highly Sensitive and Reliable Method for Detecting the JAK2V617F Mutation. <i>PLoS ONE</i> , 2015, 10, e0122003.	1.1	5
75	Mutant molecular chaperone activates cytokine receptor as a homomultimer. <i>Oncotarget</i> , 2018, 9, 35201-35202.	0.8	5
76	Epstein-Barr virus-positive multiple myeloma developing after immunosuppressant therapy for rheumatoid arthritis: a case report and review of literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 2090-102.	0.5	5
77	A Case of Advanced Primary Thyroid Double-Hit B Cell Lymphoma in Which Complete Remission has been Maintained After High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation Performed During the Second Remission, with a Review of the Literature. <i>Indian Journal of Hematology and Blood Transfusion</i> . 2014. 30. 166-173.	0.3	4
78	Multiple Placental Infarcts in a Pregnant Woman with Essential Thrombocythemia. <i>Internal Medicine</i> , 2018, 57, 3647-3650.	0.3	4
79	Real-world, retrospective study evaluating thromboembolic events, associated risk factors, and health-care resource utilization in Japanese patients with polycythemia vera. <i>International Journal of Hematology</i> , 2020, 112, 176-184.	0.7	4
80	Peripheral T cell lymphoma, not otherwise specified with myelofibrosis: report of a case with review of the literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 4186-203.	0.5	4
81	Vitamin B6 deficiency as a cause of polyneuropathy in POEMS syndrome: rapid recovery with supplementation in two cases. <i>Hematology</i> , 2022, 27, 463-468.	0.7	4
82	Ribosomal protein L11- and retinol dehydrogenase 11-induced erythroid proliferation without erythropoietin in UT-7/Epo erythroleukemic cells. <i>Experimental Hematology</i> , 2015, 43, 414-423.e1.	0.2	3
83	A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 6313-22.	0.5	3
84	Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan. <i>Hematology</i> , 2022, 27, 157-166.	0.7	3
85	Spontaneous Regression of a Clinically-Advanced Histologically Low-Grade Follicular Lymphoma Involving the Breast: Case Report and Review of the Literature. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2014, 30, 320-324.	0.3	2
86	Three cases of relapsed/refractory multiple myeloma under hemodialysis treated with panobinostat/bortezomib/dexamethasone (FVD). <i>International Journal of Hematology</i> , 2017, 106, 581-587.	0.7	2
87	The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation. <i>Internal Medicine</i> , 2017, 56, 1705-1710.	0.3	2
88	Pleural effusion at diagnosis predicts extremely poor outcomes in patients with diffuse large B-cell lymphoma harbouring MYC rearrangement. <i>British Journal of Haematology</i> , 2019, 185, 183-187.	1.2	2
89	Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis. <i>Case Reports in Oncology</i> , 2020, 12, 834-837.	0.3	2
90	Persistent immune thrombocytopaenic purpura associated with SARS-CoV-2 infection. <i>EJHaem</i> , 2021, 2, 530-533.	0.4	2

#	ARTICLE	IF	CITATIONS
91	Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin. <i>Case Reports in Oncology</i> , 2022, 15, 263-266.	0.3	2
92	Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors. <i>Annals of Medicine</i> , 2022, 54, 1244-1254.	1.5	2
93	Safety and efficacy of anagrelide in Japanese post-marketing surveillance, with subgroup analyses on the effect of previous cytoreductive therapies, age, and starting dose. <i>International Journal of Hematology</i> , 2022, 116, 570-578.	0.7	2
94	Clinical features of acquired erythrocytosis: Low levels of serum erythropoietin in a subset of non-neoplastic erythrocytosis patients. <i>Cancer Medicine</i> , 0, , .	1.3	2
95	Guest editorial: Acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia. <i>International Journal of Hematology</i> , 2014, 100, 16-17.	0.7	1
96	Efficacy of PCR-based open reading frame typing assay for outbreak investigation of metallo- β -lactamase-producing <i>Pseudomonas aeruginosa</i> in hematology unit. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 1020-1023.	0.8	1
97	JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone. <i>Leukemia Research</i> , 2021, 100, 106496.	0.4	1
98	MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations. <i>International Journal of Hematology</i> , 2021, 114, 424-440.	0.7	1
99	Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34 + cell monitoring based on the experience from two Japanese university hospitals. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 687-696.	0.4	1
100	Transgenic Expression of Bach1 Transcription Factor Results in Down-Regulation of the p45 Target Genes in Megakaryocytic Lineage Cells.. <i>Blood</i> , 2004, 104, 1605-1605.	0.6	1
101	Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2020, 60, 26-28.	0.3	1
102	Usefulness of FDG-PET (Positron Emission Tomography) in the Discrimination between Hypoplastic Myelodysplastic Syndromes and Aplastic Anemia.. <i>Blood</i> , 2004, 104, 4738-4738.	0.6	1
103	A case of post-mogamulizumab relapse of acute-type adult T-cell leukemia/lymphoma successfully treated with mogamulizumab and etoposide. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 6278-90.	0.5	1
104	Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 9609-19.	0.5	1
105	Improvement in the Symptoms and VEGF Levels after Resection of an Extramedullary Spinal Tumor and Additional Chemotherapy in a Patient with Multiple Myeloma Complicated with POEMS Syndrome. <i>Internal Medicine</i> , 2021, 60, 3625-3630.	0.3	1
106	Hodgkin Lymphoma on Hemodialysis: A Review of Treatment and Recommendations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 805-811.	0.2	1
107	Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study. <i>International Journal of Hematology</i> , 2022, 116, 696-711.	0.7	1
108	Two Cases of Acute Myeloid Leukemia Evolving into a Chronic Myelomonocytic Leukemia-like State after Induction Therapy.. <i>Internal Medicine</i> , 1992, 31, 214-217.	0.3	0

#	ARTICLE	IF	CITATIONS
109	Diagnosis of essential thrombocythemia. Japanese Journal of Thrombosis and Hemostasis, 2021, 32, 370-375.	0.1	0
110	Looking Back on My Life of 40 Years as an Academic Person. Juntendo Medical Journal, 2021, 67, 408-413.	0.1	0
111	Heme Affects Sensitivity to Imatinib through Regulation of Nrf2 Activity in BCR/ABL-Positive Cell Lines.. Blood, 2004, 104, 2092-2092.	0.6	0
112	Identification and Expression of Two microRNA Primary Transcripts, pri-miR-223 and pri-miR-10a, in Hematopoietic Cell Lines during Cytokine-Stimulated Differentiation.. Blood, 2005, 106, 1747-1747.	0.6	0
113	Identification of a Megakaryocyte Growth and Development Factor, Thrombopoietin, as a c-Mpl Ligand. Japanese Journal of Thrombosis and Hemostasis, 1995, 6, 137-141.	0.1	0
114	A case of Waldenstrom Macroglobulinemia in which intermittent one-day administration cycles of bendamustine were effective for alleviation of nausea and maintenance of remission. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 57, 79-81.	0.3	0
115	1. Pathophysiology and Treatment Strategies of Myeloproliferative Neoplasms. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 88a-95a.	0.0	0
116	1. Pathophysiology and Treatment Strategies of Myeloproliferative Neoplasms. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1672-1684.	0.0	0
117	Abnormal Exacerbation of Moderately Differentiated Gastric Adenocarcinoma in a Patient with TAFRO Syndrome: An Impaired Tumor Immunity?. Case Reports in Oncology, 2022, 15, 7-11.	0.3	0
118	Clinical and biological relevance of CREB3L1 in Philadelphia chromosome-negative myeloproliferative neoplasms. Leukemia Research, 2022, , 106883.	0.4	0
119	Recurrent and Multiple Intracerebral Hemorrhages in Polycythemia Vera Secondary to Myelofibrosis: A Case Report and Literature Review. Case Reports in Neurology, 0, , 274-280.	0.3	0